Semi-Annual Statement Of Income

Daito Pharmaceutical Co., Ltd. - Filing #7289262

Concept 2024-06-01 to
2024-11-30
2023-06-01 to
2023-11-30
Semi-annual statement of income
Statement of income
Net sales
24,584,000,000 JPY
24,110,000,000 JPY
Cost of sales
20,205,000,000 JPY
18,920,000,000 JPY
Ordinary profit (loss)
1,470,000,000 JPY
2,314,000,000 JPY
Gross profit (loss)
4,379,000,000 JPY
5,189,000,000 JPY
Selling, general and administrative expenses
2,907,000,000 JPY
2,900,000,000 JPY
Extraordinary income
409,000,000 JPY
0 JPY
Selling, general and administrative expenses
Profit (loss) before income taxes
1,879,000,000 JPY
2,315,000,000 JPY
Operating profit (loss)
1,471,000,000 JPY
2,289,000,000 JPY
Non-operating income
73,000,000 JPY
72,000,000 JPY
Income taxes - current
839,000,000 JPY
798,000,000 JPY
Non-operating income
Interest income
0 JPY
0 JPY
Dividend income
38,000,000 JPY
36,000,000 JPY
Income taxes - deferred
-66,000,000 JPY
22,000,000 JPY
Non-operating expenses
73,000,000 JPY
46,000,000 JPY
Income taxes
1,161,000,000 JPY
821,000,000 JPY
Profit (loss)
718,000,000 JPY
1,494,000,000 JPY
Non-operating expenses
Interest expenses
51,000,000 JPY
9,000,000 JPY
Extraordinary income

Talk to a Data Expert

Have a question? We'll get back to you promptly.